Prime Medicine, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Prime Medicine, Inc. (PRME) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value of $98.47 million as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes › Debt and Equity Securities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate · last filed 2023-03-09
- 2022-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $98.47M.
- 2022-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $89.17M.
- 2021-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $68.24M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2022-12-31 | $98.47M 10-K · filed 2023-03-09 |
| 2022-09-30 | $89.17M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $68.24M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |